WASHINGTON Johnson & Johnson’s pharmaceutical firm has confirmed that it will propose 20 million doses of its vaccine against coronavirus in the United States by the end of March, receiving the authorization of federal regulators.
J&J discloses the figure in a written testimonial prior to its hearing at the Congress scheduled for March, which will revise the vacancy rate for the country. Last week, Casa Blanca officials advised that the first graduates of the J&J vaccine, who only needed one dose, would be given a limited series.
The company will increase the capacity to provide 100 million doses to the United States for the June finals. Ese suministro ayudará a que el gobierno estadounidense alcance el objiet de tener suficientes vacunas para inocular a la Mayoría de los adultos estadounidenses este año. At an international scale, the company claims to produce 1,000 million doses during 2021.
The United States Health Regulators are reviewing the inadequacy and effectiveness of the vaccine, and it is expected that this week will be decided and allowed for emergency use. The J&J series is the first in the United States to require only one dose.
The vacancies currently available developed by Pfizer and Moderna require doses that need to be administered with different weeks of difference.
The executives of both companies and others of the manufacturers of vacancies will also be tested in the March audience.